10th Jul 2020 14:21
Arix Bioscience PLC - the company which invests in biotech firms - Investee Atox Bio's drug Reltecimod shows positive effect on resolution of organ dysfunction in phase 3 Accute trial for patients with necrotizing soft tissue infection. Atox Bio has reviewed the topline results of this trial with the US Food & Drug Administration and, based on these discussions, plans to submit a new drug application in the third quarter of 2020 under accelerated approval pathway.
Current stock price: 85.66 pence
Year-to-date change: down 16%
By Evelina Grecenko; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
ARIX.L